Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for Degrader
Ascentage Pharma | November 30, 2020
Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is as of now entering IND-empowering considers.
MDM2 is a critical controller of the tumor silencer p53 and one of the most powerful inhibitors of apoptosis found hitherto. It has high articulation in tumors and assumes a critical part in the event and advancement of tumors. Official to the MDM2 protein with high proclivity, MDM2 inhibitor hinders the MDM2-p53 connections and reestablish the tumor-stifling action of p53.1 Meanwhile, these MDM2 inhibitors present a few difficulties, including portion restricting hematological poison levels, in this manner the pressing need to grow new age of MDM2-focusing on treatments in the therapy of disease. The PROTAC innovation has arisen as another and promising methodology that initiates the corruption of focused proteins through the ubiquitin-proteasome framework (UPS), and it has gotten boundless interest from both mainstream researchers and enterprises since its presentation. Contrasted with ordinary "inhabitance driven" pharmacological methodology, the "occasion driven" PROTAC innovation has numerous focal points, for example, high intensity, high selectivity, with reactant method of activity, and the capacity to target undruggable proteins.2
Prof. Shaomeng Wang, Ph.D., Co-Founder of Ascentage Pharma and Chairman of its Scientific Advisory Board, and Warner-Lambert/Parke-Davis Professor in Medicine, Professor of Internal Medicine, Pharmacology and Medicinal Chemistry, Director of Michigan Center for Therapeutic Innovation, University of Michigan, is a main specialist in the field. Through structure-work investigations of their recently found MDM2 inhibitors utilizing the PROTAC innovation, Dr. Wang's exploration group has gotten intense and viable MDM2 degraders that could adequately actuate fast debasement of MDM2. The lead MDM2 degrader has accomplished total and tough tumor relapse in a xenograft tumor model in mice3.
"As a new strategy to induce protein degradation, PROTAC has emerged as a novel modality in drug discovery," said Dr. Wang. "Studies showed, PROTAC-induced MDM2 degradation can not only enhance the potency of MDM2 inhibitors, but also maintain a long-lasting suppression of MDM2 protein levels, providing a new strategy to the treatment of MDM2-driven tumors such as leukemia. We look forward to the further development of the asset by Ascentage Pharma."
"The emergence of the PROTAC technology represents another breakthrough in the identification of small molecule drugs. The technology has received tremendous interest for its ability to target undruggable proteins," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. "We are very pleased to reach this agreement with the University of Michigan, to begin the assessment of this PROTAC-based MDM2 degrader and potentially bring this important addition to our existing pipeline. Through the assessment and potential development of the MDM2 degrader, we hope soon that it will offer an effective therapy for serious unmet medical needs."